Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

por Martin, Tom, Richardson, Paul G., Facon, Thierry, Moreau, Philippe, Perrot, Aurore, Spicka, Ivan, Bisht, Kamlesh, Inchauspé, Marlene, Casca, France, Macé, Sandrine, van de Velde, Helgi, Suzuki, Kenshi
Publicado 2022

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

por Martin, Thomas, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Špička, Ivan, Baker, Ross, Kim, Kihyun, Martinez, Gracia, Min, Chang-Ki, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Koh, Youngil, Suzuki, Kenshi, Casca, France, Macé, Sandrine, Risse, Marie-Laure, Moreau, Philippe
Publicado 2023

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

por Martin, Thomas, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Špička, Ivan, Baker, Ross, Kim, Kihyun, Martinez, Gracia, Min, Chang-Ki, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Koh, Youngil, Suzuki, Kenshi, Casca, France, Macé, Sandrine, Risse, Marie-Laure, Moreau, Philippe
Publicado 2023